Global Health Investment Corporation

Managing Partners Peter Zuromskis, a former healthcare investment banker at JPMorgan, and David Glynn, a former GlaxoSmithKline vaccines executive, jointly lead the firm. They are supported by an investment team with backgrounds in pharmaceuticals, global health policy, and development finance. Investment committee composition is not publicly detailed.

GHIC primarily executes direct equity and debt investments in product developers. The firm is not known to operate as a fund-of-funds, and its public disclosures focus on direct portfolio companies advancing specific medical technologies.

The Bill & Melinda Gates Foundation was an anchor investor in GHIC's initial fund and provides a partial guarantee facility that underwrites certain portfolio risks. The foundation does not control investment decisions, but its presence constrains the firm to a public-health mandate targeting diseases that disproportionately affect low-income populations.

GHIC does not invest in non-healthcare sectors. Within life sciences, it explicitly avoids early-stage discovery assets and pure-play commercial biotech aimed solely at high-income markets. The firm's mandate is restricted to technologies addressing infectious diseases, maternal and child health, and other conditions with significant disease burdens in low-resource settings.